home / stock / drtsw / drtsw news

DRTSW News and Press, Alpha Tau Medical Ltd. Warrant From 03/29/23

Stock Information
Company Name: Alpha Tau Medical Ltd. Warrant
Stock Symbol: DRTSW
Market: NASDAQ
Website: alphatau.com
Menu
DRTSW DRTSW Quote DRTSW Short DRTSW News DRTSW Articles DRTSW Message Board
Get DRTSW Alerts

News, Short Squeeze, Breakout and More Instantly...
DRTSW - Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit

JERUSALEM, March 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present in-pe...
DRTSW - Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank

JERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today issued the following statement on Silicon Valley Bank (SVB) in respons...

DRTSW - Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update

- Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health Canada approval to initiate a liver cancer feasibility trial - - Pursued supply chain expansion in Israel, the U.S. and Japan, including increa...

DRTSW - Alpha Tau Announces Alpha DaRT(TM) Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

- First two US patients with recurrent cutaneous squamous cell carcinoma have been treated at University Cancer Center in Houston, Texas -Up to 86 patients to be enrolled in the U.S., Canada, Europe and Israel to assess the efficacy and safety of intratumoral Alpha DaRT for ...
DRTSW - Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters

JERUSALEM, March 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli Ministry of Environmental Protection has gr...

DRTSW - Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases

JERUSALEM, March 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has received authorization from Health Canada to pro...

DRTSW - Alpha Tau to Participate in Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference

JERUSALEM, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Company plans to participate in Citi’s 2023 H...
DRTSW - Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023

JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Company plans to present at the Biotech Showcase...

DRTSW - Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

JERUSALEM, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2022 financial results and provided a corpora...

DRTSW - Alpha Tau to Present at Upcoming November Investor Conferences

JERUSALEM, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the Company will present in person at the following inv...
Previous 10 Next 10